PTX.AU · Prescient Therapeutics Limited

-

Please sign in to comment on PTX.AU

1 Comment

Admin

4 years, 1 month ago

Prescient Therapeutics Limited is currently in a long term uptrend where the price is trading 148.8% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Prescient Therapeutics Limited's total revenue sank by 8.6% to $38K since the same quarter in the previous year.

Its net income has dropped by 6.0% to $-2M since the same quarter in the previous year.

Finally, its free cash flow fell by 270.8% to $-793K since the same quarter in the previous year.

Based on the above factors, Prescient Therapeutics Limited gets an overall score of 2/5.

ISIN	AU000000PTX3
Sector	Healthcare
Industry	Biotechnology
Exchange	AU
CurrencyCode	AUD

Beta	0.57
PE Ratio	None
Target Price	0.14
Market Cap	40M
Dividend Yield	None

ABOUT

Prescient Therapeutics Limited

Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-100, a first in class compound with the ability to block an cancer growth enzyme, thereby disrupting the oncogenic Ras pathway. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

PTX.AU · Prescient Therapeutics Limited

-

Prescient Therapeutics Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Prescient Therapeutics Limited using a moving average strategy